Anaplastic Large Cell Lymphoma Active Not Recruiting Phase 1 / 2 Trials for Brigatinib (DB12267)

Also known as: Lymphomas, Anaplastic Large-Cell / Anaplastic large-cell lymphoma / Large cell (Ki-1+) lymphoma / Lymphoma, Large-Cell, Anaplastic / Anaplastic large cell lymphoma, CD30-positive

IndicationStatusPhase
DBCOND0028602 (Anaplastic Large Cell Lymphoma)Active Not Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01449461A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)Treatment